These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 30587556)
1. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556 [TBL] [Abstract][Full Text] [Related]
2. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119 [TBL] [Abstract][Full Text] [Related]
3. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer. Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325 [TBL] [Abstract][Full Text] [Related]
4. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Sun K; Zhang X; Lao M; He L; Wang S; Yang H; Xu J; Tang J; Hong Z; Song J; Guo C; Li M; Liu X; Chen Y; Zhang H; Zhou J; Lin J; Zhang S; Hong Y; Huang J; Liang T; Bai X Mol Ther; 2023 Oct; 31(10):2929-2947. PubMed ID: 37515321 [TBL] [Abstract][Full Text] [Related]
5. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154 [TBL] [Abstract][Full Text] [Related]
7. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215 [TBL] [Abstract][Full Text] [Related]